<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 50 evaluable adult patients with relapsing <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and two with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> received bisantrene by central iv catheter every 3 weeks, at doses of 350 mg/m2 for patients with adequate marrow reserve and 300 mg/m2 for those with compromised marrow reserve </plain></SENT>
<SENT sid="1" pm="."><plain>The overall response rate was 30% for 50 patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, including seven complete remissions (14%) and eight partial remissions (16%) </plain></SENT>
<SENT sid="2" pm="."><plain>Neither patient with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> responded </plain></SENT>
<SENT sid="3" pm="."><plain>The 16 patients with follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> did particularly well, with 31% attaining complete remission and 25% attaining partial remission </plain></SENT>
<SENT sid="4" pm="."><plain>Five of seven complete responders remain in remission at 16-24+ months; two have relapsed, at 13 and 20 months </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001882'>Leukopenia</z:hpo>, of brief duration, was the most common toxic effect </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001945'>Fever</z:hpo> during <z:hpo ids='HP_0001875'>neutropenia</z:hpo> occurred in 23% of courses </plain></SENT>
<SENT sid="7" pm="."><plain>There was minimal cardiotoxicity with cumulative doses of up to 7080 mg/m2 of bisantrene </plain></SENT>
<SENT sid="8" pm="."><plain>Bisantrene is an effective and well-tolerated agent for the treatment of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>